<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03247140</url>
  </required_header>
  <id_info>
    <org_study_id>JLP-1401-101-PK</org_study_id>
    <nct_id>NCT03247140</nct_id>
  </id_info>
  <brief_title>The PK Characteristics of the Co-administration of Rosuvastatin and Telmisartan/Amlodipine and JLP-1401 in Healthy Male Volunteers Volunteers</brief_title>
  <official_title>An Open Label, Randomized, Single-dose, 4-period Cross-over Study to Compare the Pharmacokinetics and Safety Following Administration of JLP-1401 and Coadministration of Rosuvastatin and Telmisartan/Amlodipine in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jeil Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jeil Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The PK Characteristics of the Co-administration of Rosuvastatin and Telmisartan/Amlodipine
      and JLP-1401 in Healthy Male Volunteers Volunteers
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 10, 2017</start_date>
  <completion_date type="Actual">November 27, 2017</completion_date>
  <primary_completion_date type="Actual">August 7, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC</measure>
    <time_frame>72hr after baseline</time_frame>
    <description>Area under the curve of telmisartan, amlodipine, rosuvastatin at 72 hours after baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>72 after baseline</time_frame>
    <description>Peak concentration of telmisartan, amlodipine, rosuvastatin at 72 hours after baseline</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Hypertension With Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>Group I (JLP-1401)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>JLP-1401(Telmisartan 80 mg, amlodipine 10 mg, rosuvastatin 20 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II(Telmisartan/Amlodipine, Rosuvastatin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Twinsta(Telmisartan 40 mg, amlodipine 5 mg) 2 tab and Crestor(rosuvastatin 20 mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JLP-1401</intervention_name>
    <description>Administration of JLP-1401(Telmisartan/Amlodipine/Rosuvastatin)</description>
    <arm_group_label>Group I (JLP-1401)</arm_group_label>
    <arm_group_label>Group II(Telmisartan/Amlodipine, Rosuvastatin)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan/Amlodipine, Rosuvastatin</intervention_name>
    <description>Administration of Temlisartan/Amlosipine(Twinsta®) and Rosuvastatin(Crestor®)</description>
    <arm_group_label>Group I (JLP-1401)</arm_group_label>
    <arm_group_label>Group II(Telmisartan/Amlodipine, Rosuvastatin)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male volunteer, age is over 19 years Body weight is over 55kg, The result of
             Body Mass Index(BMI) is not less than 17.5 kg/m2 , no more than 30.5 kg/m2

          -  Subject who has the ability to comprehend the study objectives, contents and the
             property of the study drug before participating in the trial

          -  Subject who has the ability and willingness to participate the whole period of trial

        Exclusion Criteria:

          -  Presence of medical history or a concurrent disease that may interfere with treatment
             and safety assessment or completion of this clinical study, including clinically
             significant disorders in kidney, liver, cardiovascular system, respiratory system,
             endocrine system, or neuropsychiatric system.

          -  Subjects who are allergic to investigational drug.

          -  Subjects who have a medical history which can affect the clinical trial.

          -  Systolic BP &gt; 140mmHG or Diastolic BP &gt; 90mmHg)

          -  AST or ALT &gt; X 2 UNL

          -  History of drug abuse or positive drug screening.

          -  Participation in other drug studies within 3 months prior to the drug administration.

          -  Whole blood donation within 60 days, blood component donation within 30 days or who
             got transfusion within 30days.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Min Gul Kim, MD., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chonbuk National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chonbuk National University Hospital</name>
      <address>
        <city>Jeonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 28, 2017</study_first_submitted>
  <study_first_submitted_qc>August 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 11, 2017</study_first_posted>
  <last_update_submitted>December 21, 2017</last_update_submitted>
  <last_update_submitted_qc>December 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

